Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
RegeneRx Biopharmaceuticals, Inc.
Researchers Report Thymosin B4 Protects Human Cornea Epithelial Cells Against Oxidative Damage
June 3rd, 2008
REGENERX BIOPHARMACEUTICALS, INC. (AMEX:RGN) (www.regenerx.com) reported that researchers at the Institute of Biopharmaceutical Science, National Yang-Ming University, Taipei, Taiwan, found that administering TB4 up-regulates anti-oxidative enzymes in human corneal epithelial cells supporting its role in corneal protection and resistance to oxidative damage. Oxidants, such as free radicals, are believed to cause tissue damage at the cellular level and harm DNA, mitochondria, and cell membranes, which can lead to pathologies such as skin deterioration, premature aging, and cancer. Anti-oxidants are the subject of a substantial amount of research in the pharmaceutical and cosmetic industries...
Source: Cancer Weekly (2008-06-03)
|
